RU2455994C2 - Пиримидиновые производные - Google Patents

Пиримидиновые производные Download PDF

Info

Publication number
RU2455994C2
RU2455994C2 RU2009141982/04A RU2009141982A RU2455994C2 RU 2455994 C2 RU2455994 C2 RU 2455994C2 RU 2009141982/04 A RU2009141982/04 A RU 2009141982/04A RU 2009141982 A RU2009141982 A RU 2009141982A RU 2455994 C2 RU2455994 C2 RU 2455994C2
Authority
RU
Russia
Prior art keywords
methyl
indol
pyrimidin
ylamino
phenyl
Prior art date
Application number
RU2009141982/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2009141982A (ru
Inventor
Вей-Гуо СУ (CN)
Вей-Гуо СУ
Хун ЦЗЯ (CN)
Хун Цзя
Вэйхань ЧЖАН (CN)
Вэйхань ЧЖАН
Юйминь ЦУЙ (CN)
Юйминь ЦУЙ
Сяоцян ЯНЬ (CN)
Сяоцян ЯНЬ
Юнсинь ЖЭНЬ (CN)
Юнсинь ЖЭНЬ
Цзифэнь ДУАН (CN)
Цзифэнь ДУАН
Ян САЙ (CN)
Ян САЙ
Original Assignee
Хатчисон Медифарма Энтерпрайзис Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хатчисон Медифарма Энтерпрайзис Лимитед filed Critical Хатчисон Медифарма Энтерпрайзис Лимитед
Publication of RU2009141982A publication Critical patent/RU2009141982A/ru
Application granted granted Critical
Publication of RU2455994C2 publication Critical patent/RU2455994C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2009141982/04A 2007-04-16 2008-04-15 Пиримидиновые производные RU2455994C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91192107P 2007-04-16 2007-04-16
US60/911,921 2007-04-16

Publications (2)

Publication Number Publication Date
RU2009141982A RU2009141982A (ru) 2011-05-27
RU2455994C2 true RU2455994C2 (ru) 2012-07-20

Family

ID=39854302

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009141982/04A RU2455994C2 (ru) 2007-04-16 2008-04-15 Пиримидиновые производные

Country Status (17)

Country Link
US (2) US8349859B2 (enExample)
EP (1) EP2154967B9 (enExample)
JP (1) JP5635398B2 (enExample)
KR (1) KR101424847B1 (enExample)
BR (1) BRPI0809715A2 (enExample)
CA (1) CA2684470C (enExample)
DK (1) DK2154967T5 (enExample)
ES (1) ES2465673T3 (enExample)
HR (1) HRP20140377T2 (enExample)
MX (1) MX2009011199A (enExample)
NZ (1) NZ580671A (enExample)
PL (1) PL2154967T3 (enExample)
PT (1) PT2154967E (enExample)
RU (1) RU2455994C2 (enExample)
SI (1) SI2154967T1 (enExample)
TW (1) TWI484960B (enExample)
WO (1) WO2008128231A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2701188C2 (ru) * 2015-02-27 2019-09-25 Нэнтбайосайенс, Инк. Производные пиримидина в качестве ингибиторов киназы и их терапевтические применения

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
TWI491605B (zh) 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
JP2012197231A (ja) * 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
US8466155B2 (en) 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
CN102070618B (zh) * 2009-11-23 2013-08-21 和记黄埔医药（上海）有限公司 一种化合物及其晶体
BR112012029647A2 (pt) 2010-05-21 2016-08-02 Chemilia Ab novos derivados de pirimidinas
EP2395001A1 (en) 2010-05-21 2011-12-14 Chemilia AB Novel pyrimidine derivatives
EP2433636A1 (en) * 2010-09-27 2012-03-28 Medizinische Universität Wien Treatment of Malignant Diseases
EP2621276B1 (en) * 2010-09-30 2017-12-27 Merck Sharp & Dohme Corp. 2-alkoxy pyrimidine pde10 inhibitors
EP2502924A1 (en) 2011-03-24 2012-09-26 Chemilia AB Novel pyrimidine derivatives
DK2688883T3 (en) 2011-03-24 2016-09-05 Noviga Res Ab pyrimidine
WO2013054351A1 (en) * 2011-08-08 2013-04-18 Cadila Healthcare Limited Heterocyclic compounds
EP2711364A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
EP2711365A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
RU2674249C2 (ru) * 2012-11-05 2018-12-06 НэнтБайо, Инк. Замещенные производные индол-5-ола и их терапевтическое применение
CA2906185A1 (en) 2013-03-15 2014-09-18 Nantbioscience, Inc. Substituted indol-5-ol derivatives and their therapeutic applications
CN105601573B (zh) * 2014-11-24 2021-07-02 中国科学院上海药物研究所 2-氨基嘧啶类化合物及其药物组合物和应用
WO2017190050A1 (en) 2016-04-28 2017-11-02 Cornell University Inhibitors of soluble adenylyl cyclase
TW202115042A (zh) * 2019-06-21 2021-04-16 大陸商江蘇豪森藥業集團有限公司 芳基磷氧化物類衍生物抑制劑、其製備方法和應用
CN111004221B (zh) * 2019-12-13 2021-02-02 长治学院 一种嘧啶/苯并咪唑杂合物、制备方法及医药用途
EP4251613A4 (en) * 2020-11-27 2024-11-20 Allorion Therapeutics Inc. AMINOHETEROARYL KINASE INHIBITORS

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235741B1 (en) * 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
WO2001064655A1 (en) * 2000-03-01 2001-09-07 Astrazeneca Ab 2, 4-di(hetero-)arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents
WO2002102783A1 (en) * 2001-06-19 2002-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
US20030149041A1 (en) * 1999-12-28 2003-08-07 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
US6723726B1 (en) * 1996-07-13 2004-04-20 Smithkline Beecham Corporation Protein tyrosine kinase inhibitors
RU2005108999A (ru) * 2002-08-30 2005-08-27 Эйсай Ко., Лтд. (JP) Азотсодержащие ароматические производные

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
KR100838617B1 (ko) 1999-02-10 2008-06-16 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
AU2001237041B9 (en) * 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
AU2001277621A1 (en) * 2000-08-09 2002-03-04 Astrazeneca Ab Antiangiogenic bicyclic derivatives
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
CA2432000C (en) * 2000-12-21 2011-03-15 Glaxo Group Limited Pyrimidineamines as angiogenesis modulators
US20040092750A1 (en) * 2001-03-01 2004-05-13 Tomoyuki Hasegawa 2-methylindole-4-acetic acid, process for producing the same, and process for producing intermediate therefor
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CA2477505A1 (en) 2002-03-01 2003-09-12 Smithkline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
EP1515955A4 (en) 2002-06-17 2006-05-03 Smithkline Beecham Corp CHEMICAL PROCESS
JP2006514989A (ja) * 2002-07-29 2006-05-18 ライジェル ファーマシューティカルズ ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療および予防方法
JP2006503081A (ja) 2002-10-10 2006-01-26 スミスクライン ビーチャム コーポレーション 化学化合物
MXPA05005547A (es) 2002-11-28 2005-07-26 Schering Ag Pirimidinas inhibidoras de chk, pdk y akt, su produccion y uso como agentes farmaceuticos.
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
WO2005026129A1 (en) * 2003-09-15 2005-03-24 Gpc Biotech Ag Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
US20070105839A1 (en) * 2003-09-18 2007-05-10 Patricia Imbach 2, 4-Di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
US20050171171A1 (en) * 2003-11-13 2005-08-04 Ambit Biosciences Corporation Amide derivatives as FLT-3 modulators
US7718697B2 (en) 2003-12-17 2010-05-18 Alcon, Inc. Method for treating glaucoma comprising administering α-lipoic acid
EA009994B1 (ru) 2003-12-23 2008-06-30 Пфайзер Инк. Новые хинолиновые производные
DE102004044556A1 (de) * 2004-09-15 2006-03-30 Bayer Healthcare Ag Behandlung viraler Infektionen durch selektive Zerstörung virusinfizierter Zellen mit Stresskinase-Inhibitoren
US7919487B2 (en) * 2004-11-10 2011-04-05 Synta Pharmaceuticals Corporation Heteroaryl compounds
US7851466B2 (en) * 2004-11-19 2010-12-14 Synta Pharmaceuticals Corp. Pyrimidine compounds and uses thereof
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
WO2006071079A1 (en) 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
US20060247263A1 (en) * 2005-04-19 2006-11-02 Amgen Inc. Substituted heterocyclic compounds and methods of use
WO2007027238A2 (en) * 2005-05-03 2007-03-08 Rigel Pharmaceuticals, Inc. Jak kinase inhibitors and their uses
WO2006138304A2 (en) 2005-06-14 2006-12-28 Taigen Biotechnology Pyrimidine compounds
US20090149467A1 (en) * 2005-09-15 2009-06-11 Merck & Co., Inc. Tyrosine Kinase Inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723726B1 (en) * 1996-07-13 2004-04-20 Smithkline Beecham Corporation Protein tyrosine kinase inhibitors
US6235741B1 (en) * 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
US20030149041A1 (en) * 1999-12-28 2003-08-07 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
WO2001064655A1 (en) * 2000-03-01 2001-09-07 Astrazeneca Ab 2, 4-di(hetero-)arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents
WO2002102783A1 (en) * 2001-06-19 2002-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
RU2005108999A (ru) * 2002-08-30 2005-08-27 Эйсай Ко., Лтд. (JP) Азотсодержащие ароматические производные

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2701188C2 (ru) * 2015-02-27 2019-09-25 Нэнтбайосайенс, Инк. Производные пиримидина в качестве ингибиторов киназы и их терапевтические применения

Also Published As

Publication number Publication date
NZ580671A (en) 2012-03-30
RU2009141982A (ru) 2011-05-27
EP2154967B9 (en) 2014-07-23
JP2010524952A (ja) 2010-07-22
PT2154967E (pt) 2014-06-05
PL2154967T3 (pl) 2014-08-29
AU2008240084A1 (en) 2008-10-23
WO2008128231A1 (en) 2008-10-23
DK2154967T3 (da) 2014-04-07
ES2465673T9 (es) 2014-11-14
MX2009011199A (es) 2010-03-17
EP2154967B1 (en) 2014-03-05
JP5635398B2 (ja) 2014-12-03
KR20100016592A (ko) 2010-02-12
US8349859B2 (en) 2013-01-08
EP2154967A1 (en) 2010-02-24
TW200848049A (en) 2008-12-16
HRP20140377T2 (hr) 2015-01-16
US20080255172A1 (en) 2008-10-16
KR101424847B1 (ko) 2016-07-08
TWI484960B (zh) 2015-05-21
HRP20140377T1 (en) 2014-05-23
BRPI0809715A2 (pt) 2019-11-05
CA2684470C (en) 2016-02-09
EP2154967A4 (en) 2010-05-19
CA2684470A1 (en) 2008-10-23
US8901143B2 (en) 2014-12-02
DK2154967T5 (en) 2014-11-17
SI2154967T1 (sl) 2014-06-30
US20130065890A1 (en) 2013-03-14
ES2465673T3 (es) 2014-06-06

Similar Documents

Publication Publication Date Title
RU2455994C2 (ru) Пиримидиновые производные
CN101723936B (zh) 激酶抑制剂及其在药学中的用途
TWI458724B (zh) 喹唑啉衍生物
CN102741256B (zh) 对于蛋白激酶具有抑制活性的双环杂芳基衍生物
RU2505534C2 (ru) Производные хиназолина, ингибирующие активность egfr
CN105541836A (zh) 激酶抑制剂的前药形式及其在治疗中的用途
CN101289444B (zh) 一种嘧啶衍生物及其医药用途
US8501957B2 (en) Benzimidazole compounds and their use as anticancer agents
AU2008240084B2 (en) Pyrimidine derivatives
US7737157B2 (en) Pyrimidine compounds
CN112625025B (zh) 吡啶基取代的喹啉类衍生物及其制备方法和用途